560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prio... von Pedrazzoli, A.B. Azaro, Moreno, V., Gomez-Roca, C.A., Even, C., Cassier, P., Guerrero, T.C. Hernandez, de Miguel, M., Korakis, I., Purcea, D., Roy, E., Gollmer, K., Riff, C., Szyldergemajn, S.A., Calvo, E.

Volltext

918MO Molecular enrichment and outcomes based on ESCAT levels in metastatic salivary gland tumours (mSGT) patients (pts) treated in early clinical trials von Hernando-Calvo, A., Rezqallah Aron, M.A., Pedrazzoli, A.B. Azaro, Vieito, M., Saavedra Santa Gadea, O., Aguilar, S., Galvão, V., Berché, R., Alonso Casal, G., Bescós, C., De Pablo, A., Lorente, J., Giralt, J., Benavente, S., Temprana-Salvador, J., Alberola, M., Dienstmann, R., Felip, E., Garralda, E., Braña, I.

Volltext

1068P Rescue chemotherapy (CT) after immune-oncology (IO) drugs in patients (pts) with refractory solid tumours: A propensity score (PS) matched cohort study von Galvão, V., Montañá, F.J. Ros, Matos, I., Viaplana, C., Javierre, G. Villacampa, Braña, I., Pedrazzoli, A.B. Azaro, Villar, M. Vieito, Santa Gadea, O. Saavedra, Casal, G. Alonso, Hernando-Calvo, A., Carles, J., Mercade, T. Macarulla, Couselo, E. Munoz, Elez, E., Felip, E., Tabernero, J., Dienstmann, R., Oliveira, M., Garralda, E.

Volltext

562P Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOTCH transcription complex von Pedrazzoli, A.B. Azaro, Garcia, J.M. Perez, Cortés, J., Miranda, E. Lopez, Colombo, I., Garralda, E., Hess, D., Nuciforo, P.G., Vivancos, A., Ferrarotto, R., Schoenborn-Kellenberger, O., Jorga, K., Vigolo, M., Beni, L., Lehal, R., Murone, M., Bauer, M., Pisa, P., Vogl, F.D., Stathis, A.

Volltext

1025MO First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients... von Melero, I., Sanmamed, M.F., Calvo, E., Moreno, I., Moreno, V., Guerrero, T.C. Hernandez, Martinez-Garcia, M., Rodriguez-Vida, A., Tabernero, J., Pedrazzoli, A.B. Azaro, Spanggaard, I., Rohrberg, K.S., Guarin, E., Nueesch, E., Chesne, E., Ceppi, M., Sweere, U., McIntyre, C., Lichtenegger, F.S., Krieter, O.

Volltext

380P Ten-year experience of the Vall d’Hebron Institute of Oncology early drug development unit (VHIO-UITM) treating patients (pts) with primary CNS tumours (pCNS) von Gonzalez, N. Saoudi, Villar, M. Vieito, Pedrazzoli, A.B. Azaro, Braña, I., Garcia-Alvarez, A., Montañá, F.J. Ros, Barcelo, R. Berchel, Gonzalez, M., Santa Gadea, O. Saavedra, Casal, G. Alonso, Galvao de Aguiar, V., Hernando-Calvo, A., Worham, N. Ann, Sole-Domenech, M., Sanchez, J. Llavall, Martinez-Ricarte, F., Saez, E. Martinez, Carles, J., Dienstmann, R., Garralda, E.

Volltext

573P Efficacy of immunotherapy (IT) after prior immune checkpoint inhibitors (ICIs) exposure von Hernando-Calvo, A., Valdivia, A., Santa Gadea, O. Saavedra, Braña, I., Berché, R., Matos, I., Vieito, M., Pedrazzoli, A.B. Azaro, Casal, G. Alonso, Galvão, V., Garcia, M. Diez, Verdaguer, H., Velez, C. Ortiz, Gonzalez, M., Argota, I. Baraibar, Callejo, A., Couselo, E. Munoz, Tabernero, J., Dienstmann, R., Garralda, E.

Volltext

531MO VHIO immune gene-expression signature (VIGex) to enrich patient selection in immunotherapy (IT) phase I clinical trials von Hernando-Calvo, A., Mancuso, F.M., Braña, I., Santa Gadea, O. Saavedra, Vieito, M., Casal, G. Alonso, Galvao de Aguiar, V., Pedrazzoli, A.B. Azaro, Matos, I., Berché, R., Worham, N. Ann, Saura, C., Martinez, G. Argiles, Elez, E., Couselo, E. Munoz, Felip, E., Seoane, J., Tabernero, J., Vivancos, A., Garralda, E.

Volltext

572P Limited efficacy of immunotherapy combination regimens in patients with unselected “cold” tumours enrolled in early clinical trials von Santa Gadea, O. Saavedra, Hernando-Calvo, A., Berché, R., Matos, I., Gardeazabal, I., Pedrazzoli, A.B. Azaro, Villar, M. Vieito, Braña, I., Casal, G. Alonso, Galvao de Aguiar, V., Pedrola, A., Martinez, G. Argiles, Mercadé, T. Macarulla, Capdevila, J., Cedres, S., Oaknin, A., Elez, E., Tabernero, J., Dienstmann, R., Garralda, E.

Volltext

3O VHIO immune gene-expression signature (VIGex) to enrich patient selection in immunotherapy phase I clinical trials von Hernando, A., Mancuso, F.M., Braña, I., Saavedra, O., Vieito Villar, M., Gardeazabal Gonzalez, I., Alonso Casal, G., Galvao, V., Azaro Pedrazzoli, A.B., Matos Garcia, I., Berche, R., Wornham, N.A., Saura Manich, C., Argiles Martinez, G., Élez, E., Munoz Couselo, E., Felip, E., Tabernero, J., Vivancos, A., Garralda, E.

Volltext